China’s Xi speaks with Trump by phone, discusses Taiwan and bilateral ties
WILMINGTON - AstraZeneca announced plans to invest $2 billion to expand its manufacturing operations in Maryland, nearly doubling production capacity at its Frederick biologics facility and constructing a new clinical manufacturing facility in Gaithersburg. The pharmaceutical giant, with a market capitalization of $280.75 billion and trading near its 52-week high, continues to strengthen its manufacturing footprint as part of its growth strategy.
The investment will support 2,600 jobs across both sites, including the creation of 300 new positions, according to a company press release. The expanded Frederick facility will enable increased production of existing medicines and, for the first time, manufacturing of the company’s rare disease portfolio. The Gaithersburg site will focus on developing and supplying innovative molecules for clinical trials. This expansion comes as AstraZeneca reported strong revenue growth of 13.52% in the last twelve months, reaching $58.13 billion.
Both facilities are expected to be operational by 2029 and will incorporate AI, automation and data analytics technologies while being built to high environmental standards.
"Today marks a landmark moment for Maryland and American patients," said Pascal Soriot, Chief Executive Officer of AstraZeneca. "As the state’s largest biopharmaceutical employer, we are deepening our long-standing commitment to Maryland."
Maryland Governor Wes Moore noted that the investment "affirms our reputation as a global leader in life sciences, while strengthening the U.S. medicine supply chain."
This announcement is part of AstraZeneca’s previously announced $50 billion investment plan and follows recent U.S. commitments including new facilities in Rockville, Maryland, Virginia, and Coppell, Texas.
AstraZeneca employs more than 25,000 people across 19 sites in the United States, which represents the company’s largest market by sales. In 2025, the company reported creating approximately $20 billion of overall value to the American economy.
In other recent news, AstraZeneca reported third-quarter product sales of $14.365 billion, surpassing consensus estimates of $14.031 billion. This revenue increase was largely driven by strong performances in the company’s oncology segment, with notable contributions from products such as Enhertu, Truqap, Imfinzi/Imjudo, Tagrisso, Calquence, and Datroway. Additionally, Leerink Partners raised AstraZeneca’s stock price target from $85 to $87, maintaining an Outperform rating following the earnings report. Meanwhile, the US FDA has approved AstraZeneca’s Koselugo for adult patients with neurofibromatosis type 1, based on positive results from the KOMET Phase III trial.
In other developments, AstraZeneca’s FASENRA showed significant benefits for patients with hypereosinophilic syndrome in a Phase III trial, reducing the risk of disease worsening by 65% compared to placebo. On the corporate front, AstraZeneca’s CFO, Aradhana Sarin, sold 15,000 American Depositary Shares on Nasdaq. Furthermore, CEO Pascal Soriot gifted over 136,000 ordinary shares to family members, a transaction conducted for nil consideration. These recent developments highlight AstraZeneca’s ongoing activities in both its product pipeline and corporate governance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.